We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens and Nephromics to Develop Preeclampsia Diagnostic Assays

By LabMedica International staff writers
Posted on 07 Sep 2011
Siemens Healthcare Diagnostics (Tarrytown, NY, USA) has entered into a licensing agreement with Nephromics, LLC (Chestnut Hill, MA, USA) to develop two assays to be used as an aid in the diagnosis of preeclampsia.

The assays being developed are for the detection of two biomarkers, soluble fms-like tyrosine-kinase-1 (SFLT-1) and placental growth factor (PLGF). Clinical studies have shown that these two assays, when used in conjunction with each other, are better predictors of preeclampsia than either marker alone. Under the terms of the agreement, Siemens Healthcare Diagnostics will obtain rights for the development of the SFLT-1 and PLFG assays.

The addition of these assays will complement Siemens’ existing portfolio of integrated OB/GYN diagnostic solutions, which include both ultrasound imaging and reproductive endocrinology laboratory testing. Healthcare professionals are looking to the integration of in vitro and in vivo diagnostics in the practice of maternal/fetal diagnostic medicine.

Preeclampsia affects at least 5% to 8% of all pregnancies and is a leading cause of  maternal and fetal mortality. Currently, the standard methodologies for prescreening pregnant women at risk for preeclampsia are routine blood pressure monitoring and testing for protein in the urine during prenatal visits. However, with these methods, preeclampsia is often diagnosed at an advanced stage when there are limited treatment options.

“Given the prevalence and associated mortality with preeclampsia, clinicians need better diagnostic tools to identify the condition before it becomes advanced,” said Dave Hickey, CEO, Chemistry, Immunoassay, Automation, and Diagnostics IT Business Unit, Siemens Healthcare Diagnostics. “The development of assays designed to detect preeclampsia earlier is an evolving area of diagnostic medicine, and we are excited to enter into the agreement with Nephromics to offer these diagnostic solutions to our customers, clinicians, and patients.”

Related Links:

Siemens Healthcare Diagnostics







Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Latest Industry News

AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
07 Sep 2011  |   Industry

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
07 Sep 2011  |   Industry

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
07 Sep 2011  |   Industry